LEDIFOS – AN EFFECTIVE DRUG FOR THE TREATMENT OF HEPATITIS C Ledifos (Harvoni) is a unique drug intended for the treatment of chronic hepatitis C. Ledifos is an American generic, similar to the well-known medical drug Harvoni from Gilead Science. The drug is manufactured in India by Hetero Healthcare Ltd , which is a leader in the manufacture of antiviral drugs. Manufacturer Ledifos officially patented and received a license to manufacture and sell this medicine. Many drugs in this group are quite expensive, but the Indian generic Lowest price Harvoni India . In the course of long-term experimental studies, in which more than 1,600 patients with hepatitis C of the first genotype participated, the comparatively low toxicity of the drug was confirmed. The main goal was to obtain a sustained virological response upon completion of the test. After 3 months of taking the medication, 95% of patients showed positive results; by the end of therapy, the virus was not present in their
Sorafenib (generic name - Sorafenat from the Indian company Natco Pharma) - antitumor agent. It is a low molecular weight multi-kinase inhibitor. It provides a reduction in the proliferation of tumor cells in vitro. It was shown that it suppresses both intracellular kinases (serine/threonine kinases c-CRAF, BRAF, and mutant BRAF), and receptor tyrosine kinases located on the cell surface. According to recent data, some of these kinases play a key role in the processes of angiogenesis and apoptosis. In clinical trials, sorafenib inhibits tumor growth in renal cell and hepatocellular carcinoma in humans. As a means used in the treatment of renal cell carcinoma, sorafenib was officially recognized: in the USA - in December 2005 (approved by the Food and Drug Administration, FDA), in the European Union - in July 2006. As a treatment for hepatocellular carcinoma (the most common type of liver cancer), sorafenib was approved by the European Commission in October 2007 and approved